ARTICLE | Company News
Lilly joins DMD consortium
December 22, 2016 12:10 AM UTC
The Collaborative Trajectory Analysis Project (cTAP) said Eli Lilly and Co. (NYSE:LLY) has joined the consortium. The group, which includes scientists, drug companies, patient advocacy organizations and clinical centers, is collaborating to advance treatments for Duchenne muscular dystrophy.
cTAP said Lilly will contribute data from its Phase III trial of tadalafil (LY450109) to the collaboration’s natural history database for DMD. In February, Lilly said tadalafil showed no evidence of a meaningful effect on disease progression in the study (see BioCentury Extra, Feb. 4)...
BCIQ Company Profiles